We are live on ! Find out more
APTO

Aptose Biosciences, Inc.

Delisted

APTO was delisted on the 1st of April, 2025.

51 hedge funds and large institutions have $207M invested in Aptose Biosciences, Inc. in 2020 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 36 (+3)

100% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 9

19% more capital invested

Capital invested by funds: $174M → $207M (+$33.1M)

9% less funds holding

Funds holding: 5651 (-5)

23% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 22

56% less call options, than puts

Call options by funds: $578K | Put options by funds: $1.3M

Holders
51
Holders Change
-5
Holders Change %
-8.93%
% of All Funds
1.12%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.13%
New
17
Increased
18
Reduced
9
Closed
22
Calls
$578K
Puts
$1.3M
Net Calls
-$723K
Net Calls Change
-$1.22M

APTO Hedge Fund Activity: Q1 2020 in Review

51 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q1 2020, worth a combined $207M — up 19% from $174M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of APTO and 17 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 18 added.

The largest buyer was Polar Capital, adding an estimated $16.9M. The largest seller was Ikarian Capital, exiting entirely with an estimated $5.72M sold.

  • 51 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q1 2020, down from 56 in Q4 2019.
  • Funds reported $207M of Aptose Biosciences, Inc. stock for Q1 2020, up 19% quarter-over-quarter.
  • 17 funds opened new Aptose Biosciences, Inc. positions in Q1 2020 and 22 closed out, a net change of -5 holders.
  • The largest Aptose Biosciences, Inc. buyer in Q1 2020 was Polar Capital, an estimated $16.9M added.
  • The largest Aptose Biosciences, Inc. seller in Q1 2020 was Ikarian Capital, an estimated $5.72M sold.

Based on aggregated 13F filings for Q1 2020.